Investigational drug · Phase 3
AMX0035
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Wolfram Syndrome, Progressive Supranuclear Palsy, PSP.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
11
Any phase or sponsor naming "AMX0035"
First trial start
2023
Mar 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AMX0035", any sponsor or status.
Conditions studied
As listed on its trial records.
- Wolfram Syndrome
- Progressive Supranuclear Palsy
- PSP
- Neurodegenerative Diseases
- Atypical Parkinsonism
Approved drugs for the same conditions: Parkinson's disease · Neurology · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "AMX0035" as an intervention, largest first.
- Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis TreatmentPivotal-lookingStatus unknown
Amylyx Pharmaceuticals Inc.Industry
NCT05021536 · 664 participants · Start Oct 28, 2021 · Primary completion Jan 19, 2024
Drug: AMX0035 · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 69 sites in all
- Extension Study Evaluating The Safety And Tolerability of AMX0035Pivotal-lookingCompleted
Amylyx Pharmaceuticals Inc.Industry
NCT05619783 · 352 participants · Start Dec 29, 2022 · Primary completion Oct 16, 2024
Drug: AMX0035 · For: Amyotrophic Lateral Sclerosis
Sites: Leuven, Belgium; Bron, France; Clermont-Ferrand, France · 46 sites in all
- AMX0035 and Progressive Supranuclear PalsyPivotal-lookingCompleted
Amylyx Pharmaceuticals Inc.Industry
NCT06122662 · 139 participants · Start Dec 21, 2023 · Primary completion Sep 30, 2025
Drug: AMX0035 · For: Progressive Supranuclear Palsy; PSP; Neurodegenerative Diseases and 1 more
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Fountain Valley, California · 62 sites in all
- AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingCompleted
Amylyx Pharmaceuticals Inc.Industry
NCT03127514 · 137 participants · Start Jun 22, 2017 · Primary completion Sep 25, 2019
Drug: AMX0035 · For: Amyotrophic Lateral Sclerosis; Motor Neuron Disease; Neuromuscular Diseases and 5 more
Sites: Phoenix, Arizona; Orange, California; San Francisco, California · 25 sites in all
Amylyx Pharmaceuticals Inc.Industry
NCT03533257 · 95 participants · Start Sep 14, 2018 · Primary completion Oct 22, 2020
Drug: AMX0035; Placebo · For: Alzheimer Disease
Sites: Jacksonville, Florida; Orlando, Florida; Palmetto Bay, Florida · 11 sites in all
Amylyx Pharmaceuticals Inc.Industry
NCT03488524 · 90 participants · Start Mar 29, 2018 · Primary completion Mar 1, 2021
Drug: AMX0035 · For: Amyotrophic Lateral Sclerosis; ALS
Sites: Phoenix, Arizona; Orange, California; San Francisco, California · 24 sites in all
University of WashingtonAcademic, hospital or other
NCT07699380 · 60 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: AMX0035; Placebo · For: Type 1 Diabetes (T1D); Metabolic Diseases; Glucose Metabolism Disorders and 6 more
Sites: Seattle, Washington; Amsterdam, Netherlands
- A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)Pivotal-lookingCompleted
Amylyx Pharmaceuticals Inc.Industry
NCT04516096 · 28 participants · Start Nov 22, 2020 · Primary completion Dec 30, 2022
Drug: AMX0035 · For: Amyotrophic Lateral Sclerosis
Sites: San Francisco, California; Boston, Massachusetts; Worcester, Massachusetts · 5 sites in all
Amylyx Pharmaceuticals Inc.Industry
NCT04987671 · 14 participants (planned) · Start Aug 5, 2021 · Primary completion May 11, 2022
Drug: AMX0035 · For: ALS
Sites: Gainesville, Florida
- AMX0035 in Adult Patients With Wolfram SyndromeActive, not recruiting
Amylyx Pharmaceuticals Inc.Industry
NCT05676034 · 12 participants · Start Mar 3, 2023 · Primary completion Jul 23, 2024
Drug: AMX0035 · For: Wolfram Syndrome
Sites: St Louis, Missouri
Newest research
PubMed records naming it or its code names, newest first.
- The Role of SOD1 and Oxidative Stress in Amyotrophic Lateral Sclerosis: An Overview.
Gómez-Pérez CA, Ramírez-García MÁ, Yescas-Gómez P · Int J Mol Sci 2026
- Latest progress and challenges in drug development for degenerative motor neuron diseases.
Wen X, Lan T, Su W, et al. · Neural Regen Res 2026
- Amyotrophic Lateral Sclerosis: Therapeutic Innovations and Evolving Regulatory Approaches.
Singh G, Singh S, Sarkar A, et al. · CNS Neurol Disord Drug Targets 2026
- Current and emerging therapeutic strategies for amyotrophic lateral sclerosis: from pharmacological approaches to gene and stem cell therapies.
Wang Z, Huang J, Yun D · Front Neurol 2026
- AMX0035 Mitigates Oligodendrocyte Apoptosis and Ameliorates Demyelination in MCAO Rats by Inhibiting Endoplasmic Reticulum Stress and Mitochondrial Dysfunction.
Zhang L, Bian C, Wang Y, et al. · Int J Mol Sci 2025
- Potential role of solid lipid curcumin particle (SLCP) as estrogen replacement therapy in mitigating TDP-43-related neuropathy in the mouse model of ALS disease.
Majumder P, Hsu TI, Hu CJ, et al. · Exp Neurol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.